“Mesoblast will now focus on its original strategy to first gain pediatric approval for RYONCIL, followed by label extension in the larger adult population. ”
for SI to reconsider label extension again (plan A) instead of the adult trial (plan B), this spells out to me that the directions and guidance from the FDA minutes must be quite positive.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-66
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.5¢ |
Change
0.015(1.56%) |
Mkt cap ! $1.113B | |||
| Open | High | Low | Value | Volume |
| 97.0¢ | 99.5¢ | 97.0¢ | $2.315M | 2.360M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 119971 | 97.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 99.0¢ | 24889 | 9 |
View Market Depth
| Last trade - 16.10pm 22/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |